Apheresis therapies for NMOSD attacks
A retrospective study of 207 therapeutic interventions
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received May 3, 2018
- Accepted in final form July 23, 2018
- First Published September 26, 2018.
Author Disclosures
- Ingo Kleiter, MD,
- Anna Gahlen, MD,
- Nadja Borisow, MD,
- Katrin Fischer, MD,
- Klaus-Dieter Wernecke, PhD,
- Kerstin Hellwig, MD,
- Florence Pache, MD,
- Klemens Ruprecht, MD,
- Joachim Havla, MD,
- Tania Kümpfel, MD,
- Orhan Aktas, MD,
- Hans-Peter Hartung, MD,
- Marius Ringelstein, MD,
- Christian Geis, MD,
- Christoph Kleinschnitz, MD,
- Achim Berthele, MD,
- Bernhard Hemmer, MD,
- Klemens Angstwurm, MD,
- Jan-Patrick Stellmann, MD,
- Simon Schuster, MD,
- Martin Stangel, MD,
- Florian Lauda, MD,
- Hayrettin Tumani, MD,
- Christoph Mayer, MD,
- Markus Krumbholz, MD,
- Lena Zeltner, MD,
- Ulf Ziemann, MD,
- Ralf Linker, MD,
- Matthias Schwab, MD,
- Martin Marziniak, MD,
- Florian Then Bergh, MD,
- Ulrich Hofstadt-van Oy, MD,
- Oliver Neuhaus, MD,
- Uwe K. Zettl, MD,
- Jürgen Faiss, MD,
- Brigitte Wildemann, MD,
- Friedemann Paul, MD,
- Sven Jarius, MD,
- Corinna Trebst, MD;
- on behalf of NEMOS (Neuromyelitis Optica Study Group)
- Ingo Kleiter, MD,
NONE
NONE
(1) Biogen Idec, (2) Merck, (3) Novartis, (4) Sanofi, (5) Roche
Associate editor for BMC Neurology
NONE
NONE
NONE
(1) Bayer Healthcare, (2) Chugai, (3) Roche, (4) Shire
NONE
NONE
NONE
Research support from (1) Chugai, (2) Diamed
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Anna Gahlen, MD,
NONE
NONE
(1) Sanofi Genzyme, travel reimbursement
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Nadja Borisow, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Katrin Fischer, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Klaus-Dieter Wernecke, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kerstin Hellwig, MD,
Novartis, Genzyme, Teva, Merck, Roche
NONE
Bayer Healthcare, Biogen, Merck Serono, Novartis, Teva, Sanofi Genzyme, Roche
NONE
NONE
NONE
NONE
NONE
Honoraria from Biogen, Bayer Healthcare, Teva, Sanofi, Merck and Novartis
NONE
NONE
Biogen, Bayer Healthcare, Teva, Merck and Novartis
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Florence Pache, MD,
NONE
NONE
(1) Commercial: Travel grant from Genzyme, a Sanofi Company (2) Commercial: Travel grant from Bayer (3) Commercial: Travel grant from Biogene Idec (4) Non-profit: Travel grant from ECTRIMS ( European Committee for Treatment and Research in Multiple Sclerosis)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(") Dr. Florence Pache is participant in the BIH-Charit? Clinical Scientist Program funded by the Charit?- Universit?tsmedizin Berlin and the Berlin Institute of Health. (") governmental grant to Friedemann Paul- used for 50 % of my employment: KKNMS- Bundesministerium f?r Bildung und Forschung- governmental support- Ministry in Germany (") commercial grant to Friedemann Paul- used for a short time part employment to me: Novartis- no significant conflict of interest
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Klemens Ruprecht, MD,
(1)sanofi-aventis/Genzyme (2)Novartis (3)Roche
NONE
(1)Bayer Healthcare, travel and speaker honoraria (2)Biogen Idec, travel and speaker honoraria (3)Merck Serono, travel and speaker honoraria (4)sanofi-aventis/Genzyme, travel and speaker honoraria (5)Teva Pharmaceuticals, travel and speaker honoraria (6)Novartis, travel and speaker honoraria (7)Guthy Jackson Charitable Foundation, travel honoraria
(1) PLOS ONE, Academic Editor, since 2013
NONE
(1) Neurologie in Frage und Antwort, Elsevier, 2000-2015
NONE
NONE
NONE
NONE
NONE
(1) Novartis (2) Merck Serono
(1)German Ministry of Education and Research (BMBF/KKNMS, Competence Network Multiple Sclerosis)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Joachim Havla, MD,
(1) Novartis Pharma: Advisory Boards, Honoraria for speaking engagements (2) Merck Group: Expert Meeting, Advisory Boards, Honoraria for speaking engagements (3) Roche: Advisory Boards, Honoraria for speaking engagements (4) Sanofi Genzyme: Advisory Boards (5) Santhera: Honoraria for speaking engagements
NONE
(1) Novartis Pharma: Travel expenses and personal compensations, travel organisation by the company (2) Merck Serono: Travel expenses and personal compensations, travel organisation by the company
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Friedrich-Baur Stiftung, Germany
NONE
NONE
NONE
NONE
NONE
NONE
- Tania Kümpfel, MD,
NONE
NONE
I have received travel expenses and personal compensations for lectures from Bayer Healthcare, Teva Pharma, Merck, Novartis Pharma, Sanofi-Aventis/Genzyme, CLB Behring, Roche Pharma and Biogen as well as grant support from Bayer-Schering AG, Novartis and Chugai Pharma
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Orhan Aktas, MD,
(1) Medimmune Scientific Advisory Board
NONE
(1) Bayer, travel and speaker honoraria (2) Novartis, travel and speaker honoraria (3) Biogen, travel and speaker honoraria (4) Merck Serono, travel and speaker honoraria (5) Teva, travel and speaker honoraria (6) Sanofi-Genzyme, travel and speaker honoraria (7) Roche, travel and speaker honoraria (8) Almirall, speaker honoraria
(1) PLoS ONE, Academic Editor, since 2012
NONE
NONE
NONE
(1) Novartis
NONE
NONE
NONE
(1) Novartis (2) Bayer (3) Biogen
(1) German Ministry of Science (BMBF), PI for NationNMO/KKNMS
(1) German Research Foundation (DFG)
(1) Heinrich and Erna Schaufler-Foundation (2) Walter and Ilse Rose-Foundation (3) Gemeinn?tzige Hertie-Stiftung
NONE
NONE
NONE
NONE
NONE
NONE
- Hans-Peter Hartung, MD,
Novartis; Merck Serono; Teva; Biogen Idec; Roche; Genzyme; BayerHealthcare; Sanofi; MedImmune; GeNeuro; Opexa; Octapharma; Receptos Celgene; Roche
NONE
Speaker Honoraria from: Biogen Idec Genzyme Merck Novartis Roche
editorial board member (unpaid): frontiers neurology / immunology; european journal of neurology; current opinion in neurology; nature reviews neurology;
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marius Ringelstein, MD,
NONE
NONE
1. Novartis, funding for speaking at a confeence. 2. Bayer Healthcare, funding for travel to a conference. 3. Biogen Idec, funding for travel to a conference. 4. Genzyme, funding for travel to a conference. 5. TEVA, funding for travel to a conference. 6. Merz, funding for travel to a conference. 7. Merck, funding for travel to a conference.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Christian Geis, MD,
NONE
NONE
(1) Merck-Serono, travel funding
(1) Frontiers Neurology, guest editor, 2015
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) German research council, GE 2519/3-1, from 2014 (2) German research council, TRR-SFB 166, from 2015 (3) German ministry of education, CSCC, from 2013
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Christoph Kleinschnitz, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Achim Berthele, MD,
NONE
NONE
I received funding for travel and speaker honoraria from Bayer Healthcare, Biogen, Genzyme, Merck Serono, Mylan, Novartis, Roche and Teva.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Bernhard Hemmer, MD,
Advisory Boards for F. Hoffmann-La Roche Ltd, Novartis, Bayer AG, and Genentech; he has served as DMSC member for AllergyCare and TG Therapeutics
Me or my institution have received speaker honoraria from Biogen Idec, Teva Neuroscience, Merck Serono, Medimmune, Novartis, Desitin, Hoffman-LaRoche
Excemed
Editorial board member of Jama Neurology and MS Journal
I hold part of two patents; one for the detection of antibodies a n d T c e l l s a g a i n s t K I R 4 . 1 i n a s u b p o p u l a t i o n o f M S p a t i e n t s a n d o n e f o r g e n e t i c d e t e r m i n a n t s o f neutralizing antibodies to interferon β
NONE
NONE
NONE
NONE
NONE
NONE
Chugai Pharmaceuticals
German Research foundation, German Ministry of Education and Research, EU Horizon 2020, EU IMI
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Klemens Angstwurm, MD,
NONE
NONE
commercial entity, travel funding by Alexion, Bayer, BiogenIdec, MerckSerono,Novartis, and Teva in 2009 upto 2014.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Commercial entity: clinical studies on NMOSD for Alexion and Chugai, clinical studies on multiple sclerosis for Bayer, BiogenIdec, MerckSerono, Novartis, and Roche.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jan-Patrick Stellmann, MD,
Commercial - Genzyme
NONE
(1) Commercial Genzyme - speaker honoraria (2) Commercial Biogen - speaker honoraria (3) Commercial Novartis - travel grant
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Commercial - Biogen Commercial - Genzyme
DFG Research Fellowship, STE 2593/1-1, 1 year
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Simon Schuster, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Martin Stangel, MD,
Biogen, Baxalta/Shire, CSL Behring, Grifols, MedDay, Merck-Serono, Novartis, Roche, Sanofi-Genzyme, Teva
NONE
Travel and speaker honoraria from Bayer Healthcare, Biogen, CSL Behring, Merck-Serono, Novartis, Roche, Sanofi-Genzyme, and Teva
PLoS ONE, Academic Editor; Multiple Sclerosis International, Editorial Board Member
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Biogen, Merck-Serono, Novartis, Sanofi-Genzyme, Teva
Deutsche Forschungsgemeinschaft (DFG), Bundesministerium f?r Bildung und Forschung (BMBF), EU FP7
NONE
Volkswagenstiftung
NONE
NONE
NONE
NONE
NONE
NONE
- Florian Lauda, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Hayrettin Tumani, MD,
Biogen Idec, Siemens Health, Teva Pharma, Roche, Merck.
NONE
Merck-Serono, AAN participation, 2009 TEVA, ECTRIMS participation, 2008 Biogen, ENS participation, 2009, 2010 TEVA, ENS participation, 2011 Novartis, INS participation 2013 Merck Serono, ECTRIMS participation 2013 Novartis,ENS participation 2014
Neurology, Psychiatry and Brain Research (section editor) since 2011
NONE
NONE
Several industries (Merck-Serono, Bayer, TEVA, Biogen) educational presentations, 2018-2000
NONE
NONE
NONE
NONE
Merck, Teva, Novartis, Sanofi Genzyme, Siemens Health, Biogen, Roche Diagnostics.
BMBF (KKNMS-Project) 2015-2017 DMSG 2018
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Christoph Mayer, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Markus Krumbholz, MD,
(1) Novartis, (2) Genzyme, (3) Roche
NONE
(1) Novartis, travel grant for scientific congress (2) Biogen, travel grant for scientific congress (3) Celgene, travel grant for scientific congress
NONE
NONE
NONE
NONE
(1) Genzyme
NONE
NONE
NONE
(1) Novartis
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Lena Zeltner, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ulf Ziemann, MD,
(1) CorTec GmbH
NONE
(1) Bayer Vital GmbH, speaker honorarium (2) Biogen Idec GmbH, speaker honorarium (3) Bristol Myers Squibb GmbH, speaker honorarium (4) Medtronic GmbH, speaker honorarium (5) Pfizer Pharma GmbH, speaker honorarium
(1) Clinical Neurophysiology, Editor-in-Chief, 2 years (2) Journal of Neuroscience, Associate Editor, 3 years (3) Brain Stimulation, Deputy Editor, 10 years (4) Experimental Brain Research, Editorial advisory board member, 13 years
NONE
(1) Lehrbuch Neurologie, Elsevier, 2011 (2) Das TMS Buch, Springer, 2007 (3) The Oxford Handbook of Trancranial Stimulation, Oxford University Press, 2007
NONE
NONE
NONE
(1) Biogen Idec GmbH, Investigator initiated trial (2) Janssen Pharmaceuticals NV, Investigator initiated trial (3) Servier, Investigator initiated trial
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ralf Linker, MD,
Biogen, Genzyme, Merck,Novartis, Roche, TEVA.
NONE
Biogen, Genzyme, Merck, Novartis, Roche, TEVA.
NONE
NONE
NONE
NONE
Biogen, Novartis, Roche.
NONE
NONE
NONE
Biogen, Novartis.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Matthias Schwab, MD,
(1) Merck (2) Sanofi (3) Biogen (4) Novartis (5) Roche
NONE
(1) Merck (2) Sanofi (3) Biogen (4) Novartis (5) Teva
NONE
NONE
NONE
NONE
NONE
NONE
(1) Novartis, Academic research support not attributed in the manuscript
NONE
NONE
NONE
(1) European community
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Martin Marziniak, MD,
(1)Grants, personal fees and non-financial supports from Biogen, grants and personal fees from Novartis, personal fees from Bayer Vital, Genzyme/Sanofi-Aventis, Merck- Serono, Roche and Teva outside the submitted work (2)Travel expenses from German Migraine Society and Germam Multiple Sclerosis Society outside the submitted work.
NONE
(1)Grants, personal fees and non-financial supports from Biogen, grants and personal fees from Novartis, personal fees from Bayer Vital, Genzyme/Sanofi-Aventis, Merck- Serono, Roche and Teva outside the submitted work (2)Travel expenses from German Migraine Society and Germam Multiple Sclerosis Society outside the submitted work.
NONE
NONE
NONE
NONE
NONE
See number 1.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Florian Then Bergh, MD,
Speaker honoraria and consultancy fees as a speaker and advisor from Actelion, Bayer Healthcare, Biogen, Merck Serono, Novartis, Roche, Sanofi Genzyme, and TEVA.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Support for investigator-initiated trials from Actelion, Novartis. Travel support to attend scientific meetings, through the employing institution, from Bayer Schering, Biogen, Sanofi Genzyme.
German Federal Ministry of Research; Deutsche Forschungsgemeinschaft (DFG, federal research funding agency)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ulrich Hofstadt-van Oy, MD,
Merck (2), Alexion (2)
NONE
Honoraria from Alexion (2), Bayer (2), Hormosan (2), Zambon (2) Travel grants from Abbvie (2), Merck (2), Sanofi-Genzyme (2) Reseach grants from Bayer-Schering (2), Novartis (2), Merck (2)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Oliver Neuhaus, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Uwe K. Zettl, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Speakers honoraria and travel grants from Bayer Pharma, Aventis Pharma, TEVA Pharma, Merck-Serono Pharma, Biogen-Idec Pharma.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jürgen Faiss, MD,
NONE
NONE
Bayer, Novartis, Biogen, Genzyme, B?hringer, Merck-Serono, TEVA
Fortschritte Neurologie und Psychiatrie
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Brigitte Wildemann, MD,
Brigitte Wildemann served on scientific advisory boards for Novartis, Sanofi Genzyme, Roche
NONE
Brigitte Wildemann has received personal fees from Biogen, Merck Serono, Novartis Pharmaceuticals, TEVA Pharma, and from Sanofi Genzyme
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Brigitte Wildemann reports grants from Bundesministerium f?r Forschung und Technologie, grants from Dietmar Hopp Stiftung, grants from Klaus Tschira Stiftung, grants from Merck Serono, Novartis Pharmaceuticals, and from Sanofi Genzyme
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Friedemann Paul, MD,
Novartis OCTIMS study steering committee MedImmune steering committee
NONE
speaker honoraria and travel grants from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, and Merck Serono, Alexion, Chugai, MedImmune, Shire
Academic Editor, PLoS ONE Associate Editor, Neurology Neuroimmunology and Neuroinflammation
NONE
NONE
NONE
consultancies for SanofiGenzyme, BiogenIdec, MedImmune, Shire, Alexion
NONE
NONE
NONE
Research support from from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, Alexion and Merck Serono
German Research Council (DFG Exc 257), Werth Stiftung of the City of Cologne, German Ministry of Education and Research (BMBF Competence Network Multiple Sclerosis), Arthur Arnstein Stiftung Berlin, EU FP7 Framework Program (combims.eu)
NONE
Arthur Arnstein Foundation Berlin, Guthy Jackson Charitable Foundation, National Multiple Sclerosis Society of the USA
NONE
NONE
NONE
NONE
NONE
NONE
- Sven Jarius, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Corinna Trebst, MD;
NONE
NONE
Speaker honoraria (educational efforts, CME activities) from Sanofi Genzyme, Novartis and Biogen Idec
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- on behalf of NEMOS (Neuromyelitis Optica Study Group)
- From the Department of Neurology (I.K., A.G., K.H.), St. Josef Hospital, Ruhr University Bochum; Marianne-Strauß-Klinik (I.K.), Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke, Berg; NeuroCure Clinical Research Center and Experimental and Clinical Research Center (N.B., F. Pache), Charité Universitätsmedizin Berlin, and Max Delbrueck Center for Molecular Medicine, Berlin; Department of Neurology (K.F., J.F.), Asklepios Fachklinikum Teupitz; CRO Sostana GmbH and Charité Universitätsmedizin Berlin (K.-D.W.); Department of Neurology and Clinical and Experimental Multiple Sclerosis Research Center (F.Pache, K.R.), Charité Universitätsmedizin Berlin; Institute of Clinical Neuroimmunology (J.H., T.K.), Ludwig Maximilians University, Munich; Department of Neurology (O.A., H.-P.H., M.R.), Medical Faculty, Heinrich Heine University Düsseldorf; Department of Neurology (C.G., M. Schwab), Jena University Hospital; Department of Neurology (C.K.), University Hospital Essen; Department of Neurology (A.B.), Klinikum rechts der Isar, Technische Universität München, Munich; Department of Neurology (B.H.), Klinikum rechts der Isar, Technische Universität München and Munich Cluster for Systems Neurology (SyNergy); Department of Neurology (K.A.), University Hospital Regensburg; Institute of Neuroimmunology and MS (INIMS) and Department of Neurology (J.-P.S.), University Medical Centre Hamburg-Eppendorf, HamburgKlinik und Poliklinik für Neurologie (S.S.), Universitätsklinikum Hamburg-Eppendorf; Clinical Neuroimmunology and Neurochemistry (M. Stangel), Department of Neurology, Hannover Medical School; Department of Neurology (F.L., H.T.), University of Ulm; Fachklinik für Neurologie Dietenbronn (H.T.), Akademisches Krankenhaus der Universität Ulm, Schwendi; Department of Neurology (C.M.), Goethe University Frankfurt; Department of Neurology & Stroke (M.K., L.Z., U. Ziemann), and Hertie-Institute for Clinical Brain Research, University of Tübingen; Department of Neurology (R.L.), Friedrich-Alexander University Erlangen-Nuremberg; Department of Neurology and Neurological Intensive Care (M.M.), Isar-Amper-Clinic, Munich-East, Haar; Department of Neurology (F.T.B.), University of Leipzig; Department of Neurology (U. Hofstadt-van Oy), Klinikum Westfalen, Dortmund; Department of Neurology (O.N.), SRH Krankenhaus Sigmaringen; Neuroimmunological Section (U. Zettl), Department of Neurology, University of Rostock; Molecular Neuroimmunology Group (B.W., S.J.), Department of Neurology, University of Heidelberg; NeuroCure Clinical Research Center (F. Paul), Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, and Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité–Universitätsmedizin Berlin; and Department of Neurology (C.T.), Hannover Medical School, Germany.
- Correspondence
Dr. Kleiter ingo.kleiter{at}rub.de
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Article
Pregnancy outcomes in aquaporin-4–positive neuromyelitis optica spectrum disorderMatthew M. Nour, Ichiro Nakashima, Ester Coutinho et al.Neurology, November 18, 2015 -
Articles
Myasthenia gravis and neuromyelitis optica spectrum disorderA multicenter study of 16 patientsM.I. Leite, E. Coutinho, M. Lana-Peixoto et al.Neurology, May 02, 2012 -
Article
Pregnancy in Patients With AQP4-Ab, MOG-Ab, or Double-Negative Neuromyelitis Optica DisorderNicolas Collongues, Cecilia Alves Do Rego, Bertrand Bourre et al.Neurology, February 24, 2021 -
Editor's Corner
Diagnostic and treatment challenges, a new section in N2Josep Dalmau et al.Neurology: Neuroimmunology & Neuroinflammation, October 23, 2018